Clinical Trial Update: HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

View source ↗

Summary

Alaunos Therapeutics reports termination of a Phase I/II autologous TCR-T cell trial across several solid tumors. The study focused on HLA typing and tumor neoa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Endometrial Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• Autologous TCR-T cell therapy (TCR-engineered autologous T cells)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Ovarian Cancer, Endometrial Cancer | Status: TERMINATED